Equillium, Inc. (EQ:NASDAQ) closed at $1.30 on October 15, 2026, unchanged on the day. The stock trades 63.3% below its 52-week high of $3.54 and 71.1% above its 52-week low of $0.760. Over the past year, it gained 2.4%. Equillium, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -13.33% | -36.59% | -49.81% | -35.32% | +2.36% |
In 252 trading sessions since October 14, 2025, EQ closed higher on 113 days (45%). Its best day was December 11, 2025 (+25.23%) and its worst was January 6, 2026 (-17.83%). The stock moved 10% or more in a single session 25 times. It opened at least 5% above the previous day's high 2 times.
Equillium Inc is a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, which is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.
Find more stocks like EQ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.